Pengyue Zhang, PhD

  • Affiliation: IU School of Medicine

  • Data Distributed: GWAS & WES

  • Impact & Implication: “The precision medicine approach is able to identify patient subpopulations with high risk of developing adverse drug event (ADE). The proposed study has a great potential to promote health by reducing the risk ADE.”

Pengyue Zhang, PhD

  • Affiliation: IU School of Medicine

  • Data Distributed: Chemokine/cytokine multiplex analyses, PBMC Analysis, RNA Seq, GWAS

  • Impact & Implication: “This study will identify precision repurposable drug for Alzheimer's disease. The proposed study has a great potential to accelerate: 1) advancement in the clinical practice around prevention and treatment of Alzheimer's disease, and 2) reveal the mechanism of Alzheimer's disease's development and progression.”

Kathryn Nicole Weaver, MD

  • Affiliation: IU School of Medicine & Cincinnati Children’s Hospital

  • Data Distributed: WES

  • Impact & Implication: Congenital heart disease is the most common class of birth defects, occurring in 1 in 100 live births. Valvar pulmonary stenosis (vPS) accounts for 8-12% of congenital heart disease and most often the underlying cause is unknown. Our study will investigate genetic contributors to development of vPS. This will lay the groundwork for identifying genetic determinants of health outcomes in children with vPS.

Stephanie Ware MD, PhD; Lisa Martin, PhD; Surbhi Bhatnagar, MD

  • Affiliation: IU School of Medicine & Cincinnati Children’s Hospital

  • Data Distributed: WES

Dongbing Lai, PhD

  • Affiliation: IU School of Medicine

  • Data Distributed: GWAS

  • Impact & Implication: “The findings from this study will help to understand the genetic mechanisms leading to COPD and Asthma and personalized prevention and treatment methods can be developed.”

Danielle Janosevic, DO

  • Affiliation: IU School of Medicine

  • Data Distributed: RNA seq

  • Impact & Implication: There is a critical need to predict and prevent detrimental outcomes related to systemic infections., also known as sepsis. We seek to incorporate broad-based bench to bedside data to define the timeline in sepsis which will be used to predict and prevent organ failure.

Ankit Desai, MD

  • Affiliation: IU School of Medicine

  • Data Distributed: Chemokine/cytokine multiplex analyses

Paul Bohn, PhD & Christiana Oh

  • Affiliation: University of Notre Dame

  • Data Distributed: Chemokine/cytokine multiplex analyses

Melissa Kacena, PhD

  • Affiliation: IU School of Medicine

  • Data Distributed: Chemokine/cytokine multiplex analyses

Yunlong Liu, PhD

  • Affiliation: IU School of Medicine

  • Data Distributed: WES

Sarah Elsea, PhD

  • Affiliation: Baylor College of Medicine

  • Data Distributed: Chemokine/cytokine multiplex analyses, WES, & RNA Seq

  • Impact & Implication: “The primary goal of this study is to define key biomarkers (clinical, metabolic, genomic) that will aid in the identification of individuals at greater risk for negative outcomes related to COVID infection so that preventative measures may be taken to reduce risk for morbidity and mortality due to COVID infection.”

Nianjun Liu, PhD

  • Affiliation: Indiana University

  • Data Distributed: WES

Andy Yu MD, PhD

  • Affiliation: IU School of Medicine

  • Data Distributed: Chemokine/cytokine multiplex analyses

Dongbing Lai, PhD

  • Affiliation: IU School of Medicine

  • Data Distributed: GWAS

  • Impact & Implication: “We propose to investigate how an individual’s overall genetic disease risk as measured by polygenic risk score impact longitudinal disease development and progression and identify common genetic liabilities of multiple diseases. This knowledge will help understand the disease etiologies therefore novel prevention and treatment methods can be developed to promote health and reduce harm.”

Tae-Hwi Schwantes-An, PhD

  • Affiliation: IU School of Medicine

  • Data Distributed: WES & GWAS

  • Impact & Implication: : “Our study will identify genetic markers that can identify patients who receive statin drugs that are at increased risk for DILI. Using the markers, our research can be implemented in clinical settings to assess risk for DILI to patients prior to prescribing statin class drugs.”

Charlie Dong, PhD

  • Affiliation: IU School of Medicine

  • Data Distributed: GWAS, Cytokine, PBMC analysis, RNA Seq

  • Impact & Implication: “It is expected that this research will shed light on the common genetic polymorphism of the PNPLA3 gene in human liver disease development.”

Dongbing Lai, PhD

  • Affiliation: IU School of Medicine

  • Data Distributed: GWAS

  • Impact & Implication: “The findings from this study will help understand the genetic mechanisms leading to glaucoma and personalized prevention and treatment methods can be developed.”

Naga Chalasani, MD & Craig Lammert, MD

  • Affiliation: IU School of Medicine

  • Data Distributed: WES & GWAS

Kavish Patidar, MD; Raj Vuppalanchi, MD; Craig Lammert, MD

  • Affiliation: IU School of Medicine

  • Data Distributed: WES & GWAS

Nick Powell, PharmD; Todd Skaar, PhD

  • Affiliation: IU School of Medicine

  • Data Distributed: WES & GWAS

  • Impact & Implication: “Clinical studies for clopidogrel did not investigate efficacy or safety specifically in NAFLD patients, limiting generalizability to this patient population. Our data suggests that people with NAFLD may not respond to clopidogrel as well as others, and we aim to determine if this is true. This study will indicate if people with NAFLD should be treated with a different anti-platelet agent to prevent cardiovascular problems.”

Reynold Ly, PhD

  • Affiliation: IU School of Medicine

  • Data Distributed: WES & WGS

  • Impact & Implication: “Re-purposing sequencing data of URDC patients for pharmacogenomics can help to further support patient care and safety by identifying those at risk for drug toxicity or inefficacy.”

Dongbing Lai, PhD

  • Affiliation: IU School of Medicine

  • Data Distributed: WES

  • Impact & Implication: Genes identified in this study can be used to help us elucidate the genetic etiology of Substance use disorders (SUD) and related diseases. In addition, these disease causing genes could potentially be the novel therapeutic targets. Derived polygenic genetic risk scores (PRS) can be used to identify high risk individuals for SUD and related diseases hence personalized prevention and treatment methods can be developed and applied.